Why AMAG Pharmaceuticals Struggled Again in Q4
When AMAG Pharmaceuticals (NASDAQ: AMAG) reported its third-quarter results in November, the drugmaker's financial numbers were overshadowed by an FDA panel recommendation that one of its biggest-selling drugs, Makena, be withdrawn from the market. There hasn't been very much good news for the company since then.
AMAG announced its 2019 fourth-quarter and full-year results before the market opened on Wednesday, and there still wasn't a lot of good news. Here are the highlights from AMAG's Q4 update.
Image source: Getty Images.
Source Fool.com
